Skip to main content
. Author manuscript; available in PMC: 2014 Dec 23.
Published in final edited form as: ACS Nano. 2013 Nov 20;7(12):10597–10611. doi: 10.1021/nn404719c

Figure 5. Enhanced carrier endocytosis as a function of NSM dose and carrier size.

Figure 5

(A) Percent of anti-M6PR/IgG (50:50) carriers internalized out of the total number of carriers associated to cells (bound plus internalized) in activated HUVECs (3 h, 37°C). Carriers were 200-nm, 1-μm, or 4.5-μm in diameter. (B) Fold increase (Δ) in the percent internalization of anti-M6PR/NSM carriers over control anti-M6PR/IgG carriers (both 50:50) for each carrier size. (C) Comparative improvement in endocytosis (Δ in B) for anti-M6PR/NSM carriers bearing 50% NSM carrier-surface coverage (50:50) over that of carriers bearing 20% coverage (80:20). Mean ± standard error of the mean. *Compares microcarriers to 200-nm carriers; #compares anti-M6PR/NSM carriers to anti-M6PR/IgG carriers, ^compares anti-M6PR/NSM:anti-M6PR/IgG of 50:50 surface-coverage to that of 80:20 carriers for each given size (p<0.05).